T1	DRUG 56 75	コハク酸メチルプレドニゾロンナトリウム
T2	DRUG 321 340	コハク酸メチルプレドニゾロンナトリウム
T3	DRUG 283 285	薬剤
T4	DISORDER 34 40	顔面神経麻痺
T5	DISORDER 112 114	瘙痒
T8	DISORDER 173 177	軽度浸潤
T9	DISORDER 212 214	異常
T10	DISORDER 244 250	毛細血管拡張
T11	DISORDER 260 266	リンパ球浸潤
T12	DISORDER 305 307	紅斑
T13	DISORDER 314 316	皮疹
T14	DISORDER 394 396	皮疹
A1	Negation T9 negated
T15	MEASURE 76 84	２４０㎎／ｄａｙ
T16	ROUTE 91 93	点滴
T17	ANATOMY 105 111	頸部～前胸部
T19	ANATOMY 162 166	ほぼ全身
T20	ANATOMY 147 149	顔面
T21	ANATOMY 150 152	頸部
T22	ANATOMY 153 156	前胸部
T26	TEST 201 207	一般血液検査
T27	TEST 208 211	尿検査
T28	TEST 223 233	皮膚病理組織学的検査
T29	TEST 341 347	パッチテスト
T30	TEST 348 353	皮内テスト
T31	TEST 354 365	薬剤リンパ球幼若化試験
T32	TEST 384 389	再投与試験
T33	ANATOMY 236 240	真皮浅層
T34	ANATOMY 251 255	血管周囲
T37	OPINION 317 319	軽快
T38	MEASURE 375 377	陰性
T40	ROUTE 379 381	点滴
T41	CHANGE_TRIGGER 292 294	中止
T42	OPINION 308 310	軽快
T43	PERSONAL_INFORMATION 0 3	４１歳
T44	PERSONAL_INFORMATION 4 5	女
T45	TIME 24 32	平成元年８月２日
A2	Temporality T45 date
T46	TIME 49 56	７月２１日より
T47	TIME 99 104	８月１日に
A4	Temporality T47 date
T48	TIME 129 133	８月２日
A3	Temporality T48 date
T49	TIME 272 278	８月２日より
T50	TIME 300 305	約１０日で
A5	Temporality T50 duration
T51	TEST 21 23	初診
T52	TEST 143 145	初診
T24	CHANGE_TRIGGER 86 88	漸減
A6	Drug_Changes T1 decrease
T7	DISORDER 179 184	瘙痒性紅斑
A7	Drug_Changes T3 stopped
A8	Sentiment T42 positive
T6	DISORDER 116 118	紅斑
A9	Sentiment T37 positive
R1	MISC Arg1:T51 Arg2:T45	
R2	TREATMENT_FOR Arg1:T1 Arg2:T4	
R3	HAS_ROUTE Arg1:T1 Arg2:T16	
R4	HAS_DOSAGE Arg1:T1 Arg2:T15	
R5	SIGNALS_CHANGE_OF Arg1:T24 Arg2:T1	
R6	HAS_TIME Arg1:T1 Arg2:T46	
R7	EXPERIENCED_IN Arg1:T5 Arg2:T17	
R8	EXPERIENCED_IN Arg1:T6 Arg2:T17	
R9	HAS_TIME Arg1:T5 Arg2:T47	
R10	HAS_TIME Arg1:T6 Arg2:T47	
R11	EXPERIENCED_IN Arg1:T8 Arg2:T20	
R12	EXPERIENCED_IN Arg1:T8 Arg2:T21	
R13	EXPERIENCED_IN Arg1:T8 Arg2:T22	
R14	EXPERIENCED_IN Arg1:T8 Arg2:T19	
R15	EXPERIENCED_IN Arg1:T7 Arg2:T20	
R16	EXPERIENCED_IN Arg1:T7 Arg2:T21	
R17	EXPERIENCED_IN Arg1:T7 Arg2:T22	
R18	EXPERIENCED_IN Arg1:T7 Arg2:T19	
R19	HAS_RESULT Arg1:T52 Arg2:T8	
R20	HAS_RESULT Arg1:T52 Arg2:T7	
R21	EXPERIENCED_IN Arg1:T10 Arg2:T33	
R22	EXPERIENCED_IN Arg1:T11 Arg2:T34	
R23	HAS_RESULT Arg1:T28 Arg2:T10	
R24	HAS_RESULT Arg1:T28 Arg2:T11	
R25	HAS_TIME Arg1:T3 Arg2:T49	
R26	SIGNALS_CHANGE_OF Arg1:T41 Arg2:T3	
R27	IS_OPINION_ABOUT Arg1:T42 Arg2:T12	
R28	IS_OPINION_ABOUT Arg1:T37 Arg2:T13	
R29	MISC Arg1:T29 Arg2:T2	
R30	MISC Arg1:T30 Arg2:T2	
R31	MISC Arg1:T31 Arg2:T2	
R32	HAS_RESULT Arg1:T29 Arg2:T38	
R33	HAS_RESULT Arg1:T30 Arg2:T38	
R34	HAS_RESULT Arg1:T31 Arg2:T38	
R35	HAS_ROUTE Arg1:T2 Arg2:T40	
R36	MISC Arg1:T32 Arg2:T2	
T18	OPINION 397 399	再現
R37	MISC Arg1:T18 Arg2:T14	
R39	REFERS_TO Arg1:T6 Arg2:T7	
R40	REFERS_TO Arg1:T13 Arg2:T12	
R41	REFERS_TO Arg1:T12 Arg2:T7	
R42	HAS_RESULT Arg1:T27 Arg2:T9	
R43	HAS_RESULT Arg1:T26 Arg2:T9	
R44	HAS_TIME Arg1:T12 Arg2:T50	
R45	EXAMINED_WITH Arg1:T6 Arg2:T52	
R46	EXAMINED_WITH Arg1:T6 Arg2:T26	
R47	EXAMINED_WITH Arg1:T6 Arg2:T27	
R48	EXAMINED_WITH Arg1:T6 Arg2:T28	
A10	Sentiment T18 negative
R38	HAS_RESULT Arg1:T32 Arg2:T14	
R49	REFERS_TO Arg1:T3 Arg2:T1	
R50	MISC Arg1:T49 Arg2:T50	
R51	HAS_TIME Arg1:T8 Arg2:T48	
R52	HAS_TIME Arg1:T7 Arg2:T48	
